Literature DB >> 17580265

Unrelated donor bone marrow transplants for severe aplastic anemia with conditioning using total body irradiation and cyclophosphamide.

Sung-Yong Kim1, Jong-Wook Lee, Jihyang Lim, Byung-Sik Cho, Ki-Seong Eom, Yoo-Jin Kim, Hee-Je Kim, Seok Lee, Chang-Ki Min, Seok-Goo Cho, Dong-Wook Kim, Woo-Sung Min, Chun-Choo Kim.   

Abstract

The outcome of unrelated donor bone marrow transplantation for aplastic anemia is inferior to that of sibling donor bone marrow transplantation because of a higher rate of transplant-related mortality (TRM), which is closely associated with the intensity of pretransplant conditioning to overcome graft rejection. We conducted a prospective trial with an intermediate to high dose of total body irradiation (TBI) in combination with a fixed dose of cyclophosphamide (120 mg/kg) to use for pretransplant conditioning for unrelated donor bone marrow transplantation in adult aplastic anemia. The number of patients who received doses of 1200, 1000, and 800 cGy of TBI were 5, 9, and 26, respectively. The corresponding probabilities of overall survival (OS) at 3 years were 40%, 44%, and 92%, respectively. The incidence of regimen-related toxicity with grade III-IV and graft rejection in the patients who received a dose of 800 cGy of TBI were 0 of 26 patients. The significant factors associated with OS were the TBI dose (800 cGy vs. >or=1000 cGy; P = .001), chronic graft-versus-host disease (less than or equal to limited vs. extensive; P = .013), the method of HLA typing for the donor-recipient matching (serologic typing vs. DNA-based typing; P = .006), and the transfusion amount before transplantation (<or=90 vs. >90 units; P = .020).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17580265     DOI: 10.1016/j.bbmt.2007.03.013

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  6 in total

Review 1.  How I treat acquired aplastic anemia.

Authors:  Phillip Scheinberg; Neal S Young
Journal:  Blood       Date:  2012-04-19       Impact factor: 22.113

Review 2.  Alternative donor transplant of benign primary hematologic disorders.

Authors:  J Tolar; P Sodani; H Symons
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

3.  Successful outcomes of second hematopoietic stem cell transplantation for graft failure in pediatric patients with severe aplastic anemia.

Authors:  Meijie He; Ruirui Gui; Yingling Zu; Zhen Li; Dao Wang; Yanna Mao; Xianjing Wang; Huili Wang; Yongping Song; Jian Zhou
Journal:  Sci Rep       Date:  2022-06-22       Impact factor: 4.996

Review 4.  Unrelated donor stem cell transplantation in acquired severe aplastic anemia: a systematic review.

Authors:  Frank Peinemann; Ulrich Grouven; Nicolaus Kröger; Max Pittler; Beate Zschorlich; Stefan Lange
Journal:  Haematologica       Date:  2009-07-31       Impact factor: 9.941

5.  Impact of pretransplant red cell transfusion on outcome after allogeneic stem cell transplantation in adult patients with severe aplastic anemia.

Authors:  S-E Lee; S-A Yahng; B-S Cho; K-S Eom; Y-J Kim; H-J Kim; C-K Min; S Lee; S-G Cho; D-W Kim; W-S Min; J W Lee
Journal:  Bone Marrow Transplant       Date:  2016-05-23       Impact factor: 5.483

Review 6.  Recent advances in treatment of aplastic anemia.

Authors:  Seung Hwan Shin; Sung Eun Lee; Jong Wook Lee
Journal:  Korean J Intern Med       Date:  2014-10-31       Impact factor: 2.884

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.